In AML, recent studies involving the genome profiling of AML via next-generation sequencing (NGS) showed that some mutated genes (e.g., ASXL1, NPM1, FLT3, TP53, CEBPA, and RUNX1) in patients with AML impacted the prognosis of these patients [12,13,14]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.